[1May 1995] Phase I project was completed;
In June, the pilot test of the second kind of new drug, rhG-CSF, began.
10 granulosin passed the test of China Institute for Drug Control;
[1June 1996] The Ministry of Health approved the human clinical trial of granulosin;
[1June 1997] Hingir (125AlaIL-2) was approved by the Ministry of Health for clinical trial;
10: rh-bFGF was approved by the Ministry of Health for clinical trial and included in the National 863 Plan;
10 Phase II project started construction, and the company obtained the Pharmaceutical Production Enterprise License.
[1May, 1998] Granulosin obtained the new drug certificate and approval number;
The second phase of the project was completed in August, and the company was renamed as Beijing Shuanglu Pharmaceutical Co., Ltd.;
[1March, 1999] Hingir obtained the new drug certificate and officially put it into production;
In September, rhIL- 1 1 passed the verification of China Institute for the Control of Pharmaceutical and Biological Products;
1 1 month rhG-CSF is listed as a national key new product.
1February rhG-CSF won the second prize of Beijing science and technology progress;
[2000 1 month] The company's production workshops of Granular Biotin and Hingir passed the drug quality certification (GMP certification) in China;
In February, rh-bFGF was listed as a major industrialization project of the National 863 Plan.
Grain Shengsu and Hingir were awarded the Excellent Product Award of Light of Science and Technology by Beijing Municipal Government;
In March, a new drug rh-bFGF was certified as a new drug and put on the market. RhIL- 1 1 was approved for clinical research in National Medical Products Administration.
In April, rh-bFGF was included in the national torch plan and funded by the National Innovation Fund.
In April, the 100-gram pilot-scale process and clinical research was listed as a project supported by the National 863 Program Fund (project number: Z 18-03-27).
In June, Xinjier was listed as a national key new product and won the second prize of Beijing Science and Technology Progress Award.
In July, it passed the accreditation of high-tech enterprises organized by the Ministry of Science and Technology and the Chinese Academy of Sciences (double high accreditation);
With the approval of Beijing Municipal People's Government on August 9th, Beijing Shuanglu Pharmaceutical Co., Ltd. was established.
/kloc-in February, the new recombinant human interleukin -2 for injection won the second prize of Beijing Science and Technology Progress Award. [200 1 year 1 month] A new recombinant human interleukin for injection-1 1 was supported by the National Enterprise Technology Innovation Fund.
In September, the new recombinant human interleukin-1 1 for injection was included in the national torch plan.
/kloc-In February, Shuanglu Medical Biotechnology Center was recognized as a municipal enterprise technology center by Beijing.
/kloc-in February, the recombinant human basic fibroblast growth factor won the first prize of Beijing Science and Technology Progress Award. [March, 2002] Shuanglu brand Hongxin Shengxue Capsule obtained the approval certificate of domestic health food and the Hygiene License of the Ministry of Health.
In April, a new drug, Fujifu (recombinant human basic fibroblast growth factor), was officially approved for production. The company was approved to set up an enterprise postdoctoral workstation.
In May, risedronate sodium and tablets (5mg, 30mg) were approved for clinical research;
In September, Lishengsu (recombinant human granulocyte colony stimulating factor) won the title of Beijing famous brand product and advanced quality management unit, and the third phase of the company's project was completed.
1 1 month The company's external recombinant human basic fibroblast growth factor, lyophilized powder for injection, tablets, capsules and granules have passed the GMP certification of China.
/kloc-in October and February, the company's two new interferon and parathyroid hormone projects were supported by the National Tenth Five-Year Major Science and Technology Program. [2003 1 month] The company passed GMP certification again.
In March, maigre (Interleukin-1 1), the second-class new drug, was the first in China to obtain the new drug certificate and production approval.
In March, Lei Ning (loratadine dispersible tablets) and Gutongning (salmon calcitonin injection) were approved for production.
In April, the new recombinant human interferon-α (122Arg) injection was approved for clinical research (approval number: 2003L00337).
In April, salmon calcitonin injection (project number: 03 1200022B) was included in the transformation project of high-tech achievements in Beijing.
In May, matrine for injection was approved for production (National Medicine Zhunzi H20030735).
In June, telmisartan capsules and tablets were approved for clinical research, with approval numbers of 2003L02074 and 2003L02073.
In June, compound metformin hydrochloride tablets were approved for clinical research, with the approval number of 2003L02 130.
In August, temozolomide capsules were approved for clinical research, and the approval number was 2003L03265.
In September, octreotide acetate injection was approved for clinical research.
/kloc-in October, the second class of heptylplatin for injection was approved for clinical research, with the approval number of 2003L03752.
10 The second-class new drug zaleplon and capsules were produced, and the approval number was: National Medicine Zhunzi H2003 1054.
1 1 month The application of recombinant new compound interferon in the prevention and treatment of atypical pneumonia has passed the preliminary examination.
12 General Manager Xu Mingbo was named as the model of the 13th Beijing Excellent Young Engineer. [2004 1 month] The company passed the GMP certification again, with the certificate number F2850. The scope of certification: tablets, capsules and raw materials (salmon calcitonin).
1 month synthesis, expression, preparation and application of human parathyroid hormone gene mutant China National Intellectual Property Administration's invention patent entered the actual examination procedure (patent publication number: CN 1465703A).
1 month The mechanism of delayed wound healing and the development and application of a new drug, genetic engineering, won the second prize of National Science and Technology Progress Award.
In March, lysozyme buccal tablets were approved by the State Food and Drug Administration.
In March, recombinant human interleukin-2 Injection Water Needle obtained the drug registration approval and new drug certificate from the State Food and Drug Administration.
National medicine standard word S20040020 and national medicine certificate word S200400 14.
April New Anti-AIDS Drug: stavudine won the third prize of Beijing Science and Technology Progress Award.
In May, Nepidil tablets, Etodol sustained-release tablets and calcium folinate for injection were approved by SFDA.
In September, the company successfully listed on Shenzhen Stock Exchange.
In September, netilmicin sulfate injection was approved by the State Food and Drug Administration for drug registration.
/kloc-in October, telmisartan tablets, bulk drugs, tropisetron hydrochloride capsules and bulk drugs were approved by the State Food and Drug Administration for drug registration and new drug certificates; Thymopeptide for injection and raw materials have been approved by the State Food and Drug Administration for drug registration.
1 1 month metformin glibenclamide tablets (Ⅰ) obtained the drug registration approval and new drug certificate from the State Food and Drug Administration. [2005 1 month] ceftazidime for injection was approved for production (national medicine standard word H20053045).
In February, "Development and application of recombinant human interleukin-11"won the third prize of Beijing Science and Technology Progress Award.
Hydroxycamptothecin injection was approved for production (National Medicine Zhunzi H20053666).
Lishengtan (lysozyme enteric-coated tablets) was approved for production.
In March, somatostatin and somatostatin for injection were approved for production.
Xin rematch (ribavirin tablets) was approved for production.
In April, Li Lifeng (cyclosporine injection) was approved for production.
Levofloxacin hydrochloride capsules, clindamycin hydrochloride injection and ceftriaxone sodium for injection were approved for production.
In May, the company was awarded the title of "Five-year Step Up" in Zhongguancun Science Park and "Independent Innovation Star Enterprise" in Haidian Park.
The registered capital of the company increased from 69 million yuan to 82.8 million yuan.
Lishengan (Granisetron Hydrochloride Injection) was approved for production.
In July, calcium folinate for injection (0.35g) was approved for production.
In August, asparaginase and asparaginase for injection were approved for production.
Telmisartan Capsule Obtained New Drug Certificate and Production Approval
In September, the company held an online exchange meeting for investors in the reform of non-tradable shares on Panorama.com.
Fructose diphosphate for injection and valaciclovir hydrochloride were approved for production.
/kloc-Luning (Simvastatin Tablets) was approved for production in October (National Medicine Zhunzi H20058534).
Thymopeptide for injection (10mg) was approved for production (national medicine standard word H20058462).
1 1 month The company completed the share-trading reform.
Shuanglu Lisheng, a holding subsidiary of the company, obtained the Pharmaceutical Production License (certificate number: Jing HZ 20050020).
Ozagrel was approved for production (National Medicine Zhunzi H20058593).
Lishengwei (ganciclovir for injection) and Lishengshu (cefoperazone sodium and sulbactam sodium for injection) were approved for production.
/kloc-in October and February, clindamycin hydrochloride capsules and sodium ozagrel for injection were approved for production.
Tropisetron Hydrochloride Injection Obtained New Drug Certificate and Production Approval [2006 1 Month] Salmon Calcitonin Injection (2ml:20ug) Obtained Production Approval (National Medicine Zhunzi H20060056).
In February, the company won the title of A-class enterprise in Beijing.
The company announced the draft stock option incentive plan.
Nicergoline and nicergoline for injection were approved for production.
Loratadine dispersible tablets (5mg) were approved for production (National Medicine Zhunzi H20060 157).
In March, pefloxacin mesylate for injection was approved for production (National Medicine Zhunzi H20064252).
In April, Clindamycin Phosphate Injection and Nimustine Hydrochloride (API) were approved for production.
Nimustine hydrochloride obtained the new drug certificate (national medicine certificate H20060284)
In May, azithromycin granules/capsules and sodium ferulate and sodium chloride injection were approved for production.
In June, asparaginase for injection, Nimustine Hydrochloride for injection, Cefenacil Sodium for injection and Yanhuning for injection were approved for production.
Recombinant human interleukin-2 injection for injection (1500,000) IU was approved for production (national medicine standard word S20060054).
In July, the company's first-class biological product "recombinant human parathyroid hormone for injection" was approved for clinical trial (approval number: 2006L0 1495).
Xinerjin (paclitaxel injection) was approved for production (National Medicine Zhunzi H20066640).
Valaciclovir hydrochloride tablets and sterilized water for injection were approved for production.
In August, Xin Ruijin (vinorelbine tartrate injection) was approved for production (National Medicine Zhunzi H20067722).
In September, the production approval of recombinant human granulocyte colony stimulating factor injection (250ug/ bottle) was obtained (National Medicine Zhunzi S20063 1 16).
/kloc-in October, Mr. Xu Mingbo, the chairman and general manager of the company, won the title of the third outstanding young entrepreneur (gold medal) in Beijing.
1 1 month The company's restricted shares were listed and circulated for the first time, and the actual number of shares that can be listed and circulated was 1 063.170,000 shares [20071month] Shuanglu Lisheng, a holding subsidiary of the company, was awarded the GMP Certificate for Drugs (certificate number: H4/month)
In February, the company won the title of key tax paying enterprise in Beijing.
The new pre-filled packaging of Lishengsu was registered and approved by the State Food and Drug Administration.
In April, the company was selected as one hundred innovative pilot enterprises in Zhongguancun Science Park, Beijing.
In July, recombinant Candida urate oxidase for injection was approved for clinical trials of new drugs.
10 A new drug "recombinant human parathyroid hormone for injection" entered the phase II clinical study.
Ou Ning (thymopentin injection) was approved for production (National Medicine Zhunzi H200702 19).
1 1 month cefuroxime sodium for injection (three specifications) obtained the production approval (National Medicine Zhunzi H20073775, H20073776, H20073777).
1 February, the freeze-dried powder injection of recombinant human basic fibroblast growth factor for external use won the GMP Certificate again [20081month], and Chairman Xu Mingbo was selected as the national candidate for the "New Century Million Talents Project".
In April, Chairman Xu Mingbo won the "2008 Capital Labor Medal" and the approval of recombinant human growth hormone for injection (4IU) for drug clinical trial (approval number: 2008L02056).
In June, the company was approved to credit the enterprise income tax for the investment in domestic equipment for technological transformation.
The production approval documents of paracetamol tramadol tablets and mycophenolate mofetil dispersible tablets were obtained (National Medicine Zhunzi H20080394 and National Medicine Zhunzi H20080403).
The company won the special contribution award of in haidian estate of zhongguancun science park for 20 years of innovation and development.
In August, raw materials of adefovir dipivoxil capsules and adefovir dipivoxil were approved for production (National Medicine Zhunzi H20080497, National Medicine Zhunzi H20080496) and new drug certificates (National Medicine Certificate H20080202, National Medicine Certificate H2008020 1).
The raw materials and tablets of "8 18 Project", a new drug, were approved by the company (2008L4 124, 2008L4 1 14).
In September, risedronate sodium tablets and raw materials were approved for production (national medicine standard word H200805 18, national medicine standard word H200805 15).
/kloc-arsenic trioxide for injection was approved for production in October (national medicine standard word H20080664).
/kloc-tablets and capsules passed GMP certification again in February [March 2009] The company and general manager Xu Mingbo both won the "Outstanding Contribution Award for the 20th Anniversary of Zhongguancun Science Park".
In April, omeprazole enteric-coated capsules and cyclosporine soft capsules were approved for production (National Medicine Zhunzi H20093308 and National Medicine Zhunzi H20093398).